Current CDMO Product Trends and Options to Consider

 

The growing demand for medicines has increased the desire to outsource drug development to CDMOs (contract drug manufacturing organizations). Previously, pharmaceutical corporations would exclusively outsource manufacturing to a CDMO pharmaceutical company due to plant capacity limits.

However, as a result of CDMOs' focused and better drug research and R&D facilities, the pharmaceutical sector is gradually shifting toward outsourcing a bigger portion of its operations, ideation, innovation, and product development.

Which Top CDMO Trends Should You Consider?

Like every other industry, different trends affect at different times due to many factors like production rate and effectiveness. Below are some current CDMO product trends:

Sustainability

It is no surprise that an increasing number of firms have made sustainability a top priority in response to the CDMO industry's large carbon footprint. Encouraged by numerous governmental efforts, many of these companies are actively embracing an environmental consciousness. This is also typified by these companies exploring innovative methods to reconcile social responsibility, economic performance, and environmental impact.

Biopharmaceutical businesses are increasingly looking for collaborations that help them achieve both their commercial and sustainability goals. This can be facilitated by any of these – carbon-neutral production facilities, less resource-intensive operations, or eco-friendly package design.

However, this trend will be doubly important for manufacturers. Along with learning how to merge new client requirements with approved processes, CDMOs will also need to develop their unique manner of approaching environmental responsibility. A CDMO pharmaceutical company that can quickly create processes that support the environment will be recognized and preferred. This will happen not only because this move will enhance the value of their services, but also because it will demonstrate their commitment to the health of the environment and social wellness.

The Supply Chain

The pandemic (we will never get tired of blaming it, such was its effect and impact) showed the pharmaceutical industry how global supply chains could be, with ease, affected. This is, after all, the pharmaceutical industry, where many things (supply chain included) are especially complicated. Supply chains in the pharmaceutical industry are also extensive, multinational, and include high-demand commodities.

Because of the pandemic effect, companies all over the globe are rethinking the global supply chain process, which includes reshoring, increasing supplier redundancy, rethinking logistics, and upgrading systems and procedures to guarantee that supplies cannot be so easily affected next time.

Going Digital

Biopharma, which has long been a technological straggler amongst other industries, has now begun a delayed, pandemic-fueled digitalization sprint. Countless firms have begun (speedily) to virtualize their workforces, move their tasks to the cloud, and use technology to keep their operations going while ensuring employee safety.

Service providers are no exception, and they show no indications of slowing down their fast digitization. AI and machine learning-powered industrial solutions are gaining traction, with automation driving considerable improvements in supply chain productivity. The pandemic effect is going to be made redundant very soon.

Conclusion

These trends are just some of the numerous ones to watch out for in the pharmaceutical industry, so watch out for more of them. Sovereign Pharmaceuticals boasts of experience in several CDMO processes. We are a solid dose CDMO, liquid manufacturing CDMO, and everything else available in the CDMO industry. Contact us to get started.

How CDMOs Have Adjusted to Industry Changes Over The Years

 

As adaptable third-party service providers, CDMOs assist pharmaceutical businesses at all phases of the drug-making process – research and development, manufacturing, and formulation and finishing. Solid dose CDMOs (and other CDMO services) have grown in popularity over the previous decade, with consolidation and mergers and acquisitions (M&A) serving as major growth drivers.

According to recent research, over 2oo publicly disclosed M&A deals involving CDMO pharmaceutical companies occurred in the past five years. This result strengthened the position of another previous research that affirmed the same for previous years, albeit on a lesser scale. Another trend captured by the new result is current market consolidation. This shows how easily new developments affect the CDMO industry.

However, here is a key question – how exactly is this affecting CDMOs, or rather, how are CDMOs adjusting to the changes that are facing the economy?

Past

CDMOs have traditionally worked on a business strategy that has primarily focused on functioning as external service providers for the production of medicines. This concept involves the acquisition of production assets from pharmaceutical businesses to increase capacity. However, in recent years, CDMOs are progressively becoming innovators, covering more elements of the pharmaceutical sector as a whole. They are slowly becoming experts in not just manufacturing, but also generating new income sources.

Present

This shift in focus has coincided with a shift in the market's merger and acquisition environment. In the last decade, for example, novel modalities (such as gene therapies and cell therapies) and innovative vaccines gaining a rise has necessitated a significant investment in new manufacturing processes and capabilities for lipid-based formulations, nucleic acids, and viral vectors.

Well-positioned CDMOs have been able to adapt their production processes to match the growing demand for smaller, more varied projects. New collaborations have emerged, allowing CDMO players to drive the rapid increase of capabilities and capacities, assisting the sector in successfully ramping up in areas such as vaccine manufacturing.

Future

CDMOs are expected to expand their new position as technological pioneers. Smaller businesses and technology leaders are increasingly being incorporated into larger corporations. Product-focused enterprises are expected to continue moving toward the CDMO pharmaceutical company service market, while CDMOs are likely to expand their product offerings. Furthermore, CDMOs looking to penetrate high-value, low-volume markets such as personalized medicine might see the integration of clinical trial services as a sign to get into the market.

It is therefore a distinct but sure possibility that going forward, CDMOs are poised to become significant contributors to pharmaceutical sector innovation. Overall, CDMOs will likely continue to be important partners for pharmaceutical firms, and their rising technological skills and know-how along the value chain will increase their significance.

Conclusion

Progress and innovation in the pharmaceutical industry are getting increasingly common, and the CDMO sub-sector is a good example of that. Ensuring you pick the right CDMO is very important, and that is where Sovereign Pharmaceuticals comes in. Sovereign Pharmaceuticals is a CDMO pharmaceutical company that doubles as a liquid manufacturing CDMO among various other services that we offer. You can contact us to get started today.

Things Stakeholders in the CDMO Sector Need to Know before 2023

 

The pharmaceutical industry is getting more holistic, and we have the CDMOs to thank for it. The CDMOs cannot take all the glory, however; after all, most of these trends emerged due to the pandemic.

While the pandemic continues to disrupt and transform industry business strategies and practices, it also provides new solutions to long-standing issues such as pricing, reimbursement, and customer engagement caused by tensions between innovation, market access, and financially-strained health systems.

Furthermore, the industry's attempts to battle the epidemic have opened up new avenues for innovation and growth. Hence, it is no surprise to see newly developed rules and policies crop up and become the norm. Here are some of these new policies:

1.      Agile Workflows

Both the Covid-19 outbreak and the ensuing digital transition among liquid manufacturing CDMOs have spurred and facilitated more flexible methods of working and thinking. One example of the advantage of agile workflow is the speedy development and approval of Covid vaccines, as well as the optimization of joint efforts and techniques.

More broadly, agile project management underscores the industry's aim to take full advantage of its ingenuity, productivity, and effectiveness, reflecting the growing concern for drug cost control. Embracing the agile method also allows for the flexibility and responsiveness required to improve the actual value of products and services. Today's pharmaceutical sector is in continual change, servicing a larger, more diverse, technologically empowered, and demanding consumer base.

By limiting face-to-face interaction and hastening the use of digital technologies and media, the pandemic has prompted many CDMO pharmaceutical companies to entirely rethink their business strategies. This is evident in clinical development, where limited access to trial venues due to Covid limitations has accelerated the use of remote or hybrid clinical studies. Companies may now better discover and categorize potential clinical trial participants using digital tools, and then tailor studies to particular patients' preferences or abilities.

Interactive data flow, remote monitoring, home care, and mobile devices for recording real-time patient outcomes in virtual/hybrid trials all open the door to novel digital endpoints in clinical trials. They may provide more accurate, fast, and complete measures of a larger variety of outcomes, better reflecting the entire patient experience.

2.     HTA adoption

The use of health technology assessment (HTA) to restrict medicine access and pricing is gaining traction across the world. However, HTA criteria and techniques can vary greatly from market to market. Although harmonizing the regulatory framework for evaluating and approving medicines in the European Union (EU) has aided in the facilitation and expedition of access to the European market, reimbursement decisions for medicines, as well as any pharmacoeconomic assessments that underpin those decisions, have always been left to individual EU member states. This can lead to severe discrepancies between markets, which are further amplified by regional and local evaluations, resulting in major delays in launches and acceptance, or, in the worst-case scenario, wholesale withdrawal from the market.

Efforts have been made to reconcile these disparities, but in recent years, the emphasis has switched toward the development of a mandated, centralized joint clinical assessment (JCA) system.

Companies are increasingly looking for a more comprehensive knowledge of drug innovation that goes beyond the rather narrow value criteria currently used by HTA authorities. This would ideally acknowledge the whole spectrum of long-term cost offsets and social benefits possible from inventions that genuinely push the limits of medicine.

Conclusion

The approaching year will provide more substantial difficulties and possibilities for pharmaceutical businesses, reflecting both organic market trends and the disruptive effects of the pandemic. However, certain companies are adjusting well, and one is Sovereign Pharmaceuticals.

Sovereign Pharmaceuticals is a major liquid manufacturing CDMO and solid dose CDMO. Contact us to get our services.

Are CDMOs Shaping Up a More Holistic Pharmaceutical Industry?

 

It is not news, but it has to be said – industry expectations for "full service" CDMOs are changing.

Many pharmaceutical firms have, in recent years, begun to limit the number of service providers with whom they engage, developing strategic alliances with contractors that offer a larger variety of services. The goal is to reduce the time to market, boost efficiency, and reduce oversight and supervision duties.

While this trend continues, other variables such as growing customer and government quality expectations have also developed, impacting the breadth of skills that a full-service contractor is required to supply.

The CDMO pharmaceutical company sector is rapidly growing as a result of certain demands being placed on this sector. These demands are helping to shape a more holistic industry, all thanks to consistent engagement. Here are some of those demands and how they are helping CDMOs:

Demand 1: CDMO Consolidation

Initially, the CDMO sector was made up of experts from different pharmaceutical sectors and subfields who provided a narrow range of services with less-than-frequent overlap into some other requirements. However, as the market has gotten more competitive over time, consolidation has occurred, with larger CDMOs purchasing these smaller specialists to increase their range of capabilities.

Since CDMOs with a broad variety of services and a worldwide footprint are ideally positioned to relieve their consumers of complexity, M&As seem a good path to tread through.

Large pharmaceutical businesses are increasingly favoring a small number of suppliers who can provide a wide range of services linked with a specific but wide range of goods. Similarly, virtual pharma firms, specialized pharma, and generic suppliers expect a comprehensive and complete set of services, including manufacturing, development, and regulatory support. 

Demand 2: Technical expertise and quality

Full-service CDMOs should also have a larger breadth of technical competence. Customer expectations reflect rising quality demands, and it’s no surprise that some are requesting that their contractors meet greater quality standards than even regulators expect.

Also, making and selling high-tech, high-value items, such as those that require lyophilization, for example, is a challenging issue. Such items, for example, might be extremely delicate, necessitating specialized equipment and expertise.

These needs are forcing full-service contractors/CDMOs to further extend their skills in a range of sectors, either via investment (VC) or purchase of (again) smaller experts that consistently handle requirements of specific nature.

Outsourced services are becoming more popular in fields such as lyophilization and sterile liquid fill & finish processes, which require expertise and large investments.

Demand 3: Manufacturing Capacity and Flexibility

Another important factor for full-service CDMOs is the rising worldwide demand for pharmaceuticals. The pharmaceutical sector is experiencing massive volume demand at the moment, and this is due to the rising aging global population and new emerging economies and markets.

Catering to rising demand necessitates increased capacity for manufacturing. The best way for a CDMO to be effective is to possess and successfully run a diversified and well-established network of companies with different specialties.

Similarly, assisting pharmaceutical businesses in supplying medicines to new economies necessitates an established and flexible production infrastructure. It also requires proper knowledge of the requirements of cost-sensitive markets.

Conclusion

The growth of the pharmaceutical business is fueling the expansion of the CDMO sector, particularly full-service contractors that spend to provide complete and cutting-edge services. CDMOs that can handle more than one service are the best option at the moment.

One such CDMO is Sovereign Pharmaceuticals. We are a solid dose CDMO, formulation development CDMO, liquid manufacturing CDMO, and many other services you require of us. Contact us if you need any of these services. And you’ll be glad you did.